Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Ceftibuten Articles

PDi to promote Shionogi antibiotic in USA

25 October 2004

Shionogi acquires US marketing rights for Cedax

13 September 2004

Tokyo pharma stocks - week to September 6

13 September 2004

FDA Year-End Approvals Round-Up

8 January 1996

USA Lags Foreign Approvals, PhRMA Demonstrates

16 October 1995

Schering-Plough Is "Right-Sized And Flexible"

3 July 1995

GEOGRAPHIC DIVERSITY KEY TO SCHERING-PLOUGH

11 July 1994

CURRENCY AND CHARGES IMPACT 1993 US RESULTS

7 February 1994

ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES

31 January 1994

SCHERING-PLOUGH NOW "MORE EFFICIENT"

10 May 1993

SHIONOGI LAUNCH

21 December 1992

ITALY'S RECORDATI LOOKS FOR EXPANSION

15 June 1992

"GREAT STRIDES" FOR SCHERING-PLOUGH

18 May 1992

EC PLENARY SESSION DECISIONS

6 January 1992

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS